Diabetes Mellitus Clinical Trial
Official title:
An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of Insulin RinGlar® ("Geropharm", Russia) Compared to Lantus® SoloStar® ("Sanofi-Aventis Deutschland GmbH", Germany) in Type 1 Diabetes Mellitus Patients
Verified date | January 2019 |
Source | Geropharm |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is designed to approve non-inferior efficacy and safety of Insulin RinGlar® compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients.
Status | Completed |
Enrollment | 180 |
Est. completion date | May 15, 2019 |
Est. primary completion date | February 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Signed written consent - Diabetes mellitus type 1 for at least 12 months prior to screening - History of basis-bolus (multiple dose injection (MDI)) therapy in stable doses at least 30 days - Glycated hemoglobin (HbA1c) level of 6.5 to 12.0 % at screening (both values inclusive) - Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive) - Subject is able and willing to comply with the requirements of the study protocol Exclusion Criteria: - Contraindication to the use of Insulin glargine - Insulin resistance over 1.5 U/kg insulin pro day - History of treatment any biosimilar insulin - History of treatment any experimental drugs or medical devices for 3 months prior to screening - History of treatment insulin pump for 90 days prior to signed written consent or indication for use insulin pump - Presence of severe diabetes complications - History of severe hypoglycemia during 6 months prior to signed written consent - History of 15 or more episodes mild hypoglycemia during 1 month prior to signed written consent - History or presence of uncontrolled diabetes mellitus for 6 months prior to screening - History of administration of glucocorticoids for 1 year prior to screening - Administration of any immunosupressive drugs (Cyclosporinum, Methotrexatum, etc.) - History of autoimmune disease, except vitiligo and controlled autoimmune polyglandular syndrome (APS) types 1-3, except adrenal insufficiency - History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions - History of severe allergic reactions - Pregnant and breast-feeding women - Acute inflammation disease for 3 weeks prior to screening - Deviation of the laboratory results conducted during the screening: Hemoglobin value < 9,0 g/dl; Hematocrit value < 30 %; ALT and AST value > 2 folds as high as maximal normal value; Serum bilirubin value > 1.5 folds as high as maximal normal value - History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, etc.) - Serious blood loss for 3 months prior to screening (blood donation, surgery procedure, etc.) - Incomplete recovery after surgery procedure - History of unstable angina, myocardial infarction, severe arrhythmia, heart failure III or IV NYHA for 1 year prior to screening - History of stroke or TIA for 6 months prior to screening - History of drug, alcohol abuse for 3 years prior to screening - Inability follow to protocol - History of oncological disease during 5 years prior to screening - Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg), hepatitis C (HCVAb) or syphilis (Treponema pallidum) antibodies at screening. - History of transplantation, except 3 months after corneal transplant - History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Arkhangelsk Regional Clinical Hospital | Arkhangel'sk | |
Russian Federation | Kazan Endocrinology Dispensary | Kazan | |
Russian Federation | Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky | Krasnoyarsk | |
Russian Federation | Endocrinology Research Centre (Moscow) | Moscow | |
Russian Federation | V.A. Baranov Republic Hospital | Petrozavodsk | |
Russian Federation | Rostov State Medical University | Rostov-on-Don | |
Russian Federation | Almazov National Medical Research Centre | Saint Petersburg | |
Russian Federation | City Diagnostic Center ? 1 | Saint Petersburg | |
Russian Federation | City Hospital ? 2 | Saint Petersburg | |
Russian Federation | City Polyclinic ? 117 | Saint Petersburg | |
Russian Federation | EosMed | Saint Petersburg | |
Russian Federation | Pokrovskaya Municipal Hospital | Saint Petersburg | |
Russian Federation | Polyclinic ?omplex | Saint Petersburg | |
Russian Federation | Clinical City Hospital ? 9 | Saratov |
Lead Sponsor | Collaborator |
---|---|
Geropharm |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Antibody Response | Change from baseline in titer of antibodies to human insulin | 26 weeks | |
Secondary | Adverse Events frequency and degree | Hypoglycemic episodes (glucose level < 3.9 mmol/l) frequency; Occurrence of local reactions at injection sites; Occurrence allergic reactions. | 26 weeks (4+22 weeks) | |
Secondary | Glycated hemoglobin | Change in HbA1c from baseline | 26 weeks | |
Secondary | Fasting Plasma Glucose Level | Change in fasting plasma glucose level from baseline | 26 weeks | |
Secondary | Seven-Point Glucose Testing | Change in seven-point glucose testing results from baseline | 26 weeks | |
Secondary | Basal Insulin Dose | Change in basal insulin dose per body weight (U/kg) from baseline | 26 weeks | |
Secondary | Total Insulin Dose | Change in total insulin dose per body weight (U/kg) from baseline | 26 weeks | |
Secondary | Body Mass Index | Change in BMI from baseline | 26 weeks | |
Secondary | Treatment Satisfaction | Change in overall treatment satisfaction (DTSQ score) from baseline | 26 weeks | |
Secondary | Achievement of Glycated Hemoglobin Goals | The frequency of achievement glycated hemoglobin goals | 26 weeks | |
Secondary | Achievement of Glycated Hemoglobin < 7% | The frequency of achievement glycated hemoglobin < 7% ( 7% inclusive) | 26 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |